RecruitingPhase 1NCT05992311

Clinical Evaluation of Montelukast in Veterans With Gulf War Illness

Clinical Evaluation of Montelukast on Cognitive and Mood Dysfunction and Neuroinflammation in Veterans With Gulf War Illness (GWI)

Sponsor

Baylor College of Medicine

Enrollment

80 participants

Start Date

Aug 15, 2025

Study Type

INTERVENTIONAL

Conditions

Gulf War Syndrome

Summary

The study addresses the pre-clinical promise of Montelukast (MLK) for improving brain function in veterans with Gulf War Illness (GWI). MLK, a US Food and Drug administration (FDA)-approved drug for asthma, has shown efficacy in an animal model of GWI to improve cognitive and mood function through modulation of leukotriene signaling and suppression of neuroinflammation.

Eligibility

Min Age: 50 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Montelukast and Placebo for people with gulf war syndrome. The study is currently recruiting participants at 1 location. People eligible for this study include aged 50 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMontelukast

This group will receive the montelukast treatment.

OTHERPlacebo

This group will receive a placebo pill instead of montelukast

Locations(1)

Michael E. DeBakey VA Medical Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05992311

Related Trials

Confirming the Effects of Acupuncture Treatments to Relieve Symptoms of Gulf War Illness

NCT0671641110 locations

Validating Gulf War Illness Blood Biomarkers

NCT057361463 locations